CMS subtypes correlate with complete response in trial of neoadjuvant Galunisertib plus chemoradiation in rectal cancer

Venkatesh Rajamanickam(Cancer Institute (WIA)), Kristina H. Young(Providence Portland Medical Center), Thomas DeSilvio(Case Western Reserve University), E. Domingo(University of Oxford), Michael J. Gough(Providence Portland Medical Center), Noah D. Simons(Providence Portland Medical Center), David O’Brien(Oregon Clinic), Brian Piening(Providence College), Wesley Rosales(Providence Portland Medical Center), Tomoko Yamazaki(Providence Portland Medical Center), Marka R. Crittenden(Providence Portland Medical Center), Maria X. Kiely(Oregon Clinic), Rehan Ahmad(Oregon Clinic), Satish Viswanath(Louis Stokes Cleveland VA Medical Center), Mark Whiteford(Oregon Clinic), Anton Kravchenko(Providence Portland Medical Center), Brady Bernard(Providence Portland Medical Center), Amanda V. Hayman(Oregon Clinic), Timothy Maughan(University of Oxford), Charlems Alvarez‐Jimenez(Military University Nueva Granada)
Translational Oncology
February 6, 2026
Cited by 0


Related Papers